1. NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC). (March 2019) Authors: Litton, J.; Symmans, F.; Gogineni, K.; Saltzman, M.; Telli, M.L.; Usha, L.; Chakrabarti, J.; Tudor, I.C.; Quek, R.G.W.; Czibere, A. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗